cobas® eplex system

IVD For in vitro diagnostic use.

Fast, reliable syndromic testing for informed therapeutic decisions

The cobas® eplex system simplifies and accelerates multiplex molecular diagnostics, from order entry to result reporting. It features true sample-to-answer workflow, bi-directional laboratory information system (LIS) integration, random and continuous access, and a scalable, modular design, to efficiently adapt to peak demand. With less than 1 minute hands-on time and remote service capabilities, the system reduces downtime while streamlining lab operations. By detecting multiple pathogens from a single patient sample in one rapid test, the cobas eplex system minimizes the need for multiple tests, saving both time and resources.

Enhanced efficiency with our comprehensive panels

With high sensitivity and specificity, all of our panels support infection control and enable rapid and effective treatment decisions, supporting clinicians in improving patient outcomes.1-4

The cobas® eplex blood culture identification panels (BCID) aid in detecting bacterial and fungal organisms and antibiotic resistance genes directly from positive blood cultures in about 1.5 hours.2-4 They offer the broadest coverage of organisms and resistance markers that cause bloodstream infections (BSIs), including anaerobes, multidrug-resistant organisms (MDROs), and emerging fungal pathogens.2-6 Their broad coverage means that about 95% of currently identified bloodstream infections can be detected early.*2-4 By enabling fast, targeted therapy, the BCID panels support sepsis management, infection control, and antimicrobial stewardship.

Comprehensive coverage of respiratory pathogens beyond influenza, such as respiratory syncytial virus (RSV) and SARS-CoV-2, is critical in patients at higher risk for complications or more severe infections. The cobas® eplex respiratory pathogen panel 2 (RP2) detects the most common viruses and bacteria causing upper respiratory illness from a single sample in about 1.5 hours.1 This supports effective infection control and respiratory illness management, particularly during high-demand seasons.

To continue addressing the growing demands of diagnostic laboratories, additional panels are in development to expand testing capabilities.**

Two lab technicians viewing a test result on the cobas eplex system
Benefits at a glance

Benefits at a glance

Overview

Ordering information

Back     Next
error errorMessage
Sorry, we couldn't find the content you are looking for
Please try again later

Explore the cobas eplex system

Image of the cobas eplex 3-bay system, with three test bays. The onscreen interface shows three available bays.

A scalable and modular solution: 3-bay system

  • 3 test bays

  • Throughput (24 hours)†: 42 samples

  • Physical dimensions (H x D x W): 60 x 48 x 52 cm, 24” x 19” x 20”

Read more
Image of the cobas eplex 1-tower system, with 6 test bays. The onscreen interface shows six available bays.

1-tower system

  • 6 test bays

  • Throughput (24 hours)†: 84 samples

  • Physical dimensions (H x D x W): 60 x 48 x 52 cm, 24” x 19” x 20”

Read more
Image of the cobas eplex 2-tower system, with 12 test bays. The onscreen interface shows 12 available bays.

2-tower system

  • 12 test bays

  • Throughput (24 hours)†: 168 samples

  • Physical dimensions (H x D x W): 60 x 48 x 71 cm, 24” x 19” x 28”

Read more
 Image of the cobas eplex 3-tower system, with 18 test bays. The onscreen interface shows 18 available bays.

3-tower system

  • 18 test bays

  • Throughput (24 hours)†: 252 samples

  • Physical dimensions (H x D x W): 60 x 48 x 90 cm, 24” x 19” x 36”

Read more
Image of the cobas eplex 4-tower system, with 24 test bays. The onscreen interface shows 24 available bays.

4-tower system

  • 24 test bays

  • Throughput (24 hours)†: 336 samples

  • Physical dimensions (H x D x W): 60 x 48 x 110 cm, 24” x 19” x 43”

Read more

Related products

Contact us

Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.

*Based on ePlex Panel inclusivity compared to 2 representative US clinical data sets (not intended as sensitivity/performance claims): i) The GenMark prospective clinical study database (n=1,978); ii) 12 months of BCID clinical isolate data from 5 geographically diverse US hospitals (n=15,793).

**An updated version of the respiratory pathogen panel and a meningitis & encephalitis panel are currently in development and are not available for sale.

†Based on 24 hour day

References:

  1. GenMark Diagnostics, Inc. cobas® eplex respiratory pathogen panel 2 Method Sheet (v2.0). 2025.

  2. GenMark Diagnostics, Inc. cobas® eplex blood culture identification gram-positive (BCID-GP) panel Method Sheet (v1.0). 2024.

  3. GenMark Diagnostics, Inc. cobas® eplex blood culture identification gram-negative (BCID-GN) panel Method Sheet (v1.0). 2024.

  4. GenMark Diagnostics, Inc. cobas® eplex blood culture identification fungal panel (BCID-FP) Package insert. (vC). 2024.

  5. bioMerieux. BioFire Blood Culture Identification 2 (BCID2) Panel package insert. FIT-PRT-0841-02 June 2020.

  6. Nanosphere Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) package insert. 27- 00030-01, Rev. B; October 2012.

  7. GenMark Diagnostics, Inc. cobas® eplex® System Instrument Software 3.0 User Assistance (v1.0) 2024.

  8. bioMerieux. BIOFIRE FilmArray Torch Operators Manual, HTFA-PRT-0001-09, 2023.

  9. Qiagen, QIAstat-Dx Analyzer 1.0 User Manual, HB-2942-001, 2021.

  10. Makary MA and Michael D. Medical error—the third leading cause of death in the US. BMJ. 2016;353:i2139.

  11. The National Academics of Sciences, Engineering, and Medicine. [Internet; cited 2017 Apr 20]. Available from: https://www.nap.edu/read/9728/chapter/4#39.